Experts weigh benefits, risks of Allergan-Inamed merger

Article

National report — A proposed $3.2 billion merger of Botox-maker Allergan and breast-implant maker Inamed would ultimately benefit dermatologists, an Allergan official says.

Related Videos
Related Content

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Periorbital Rejuvenation: Comprehensive Assessment and Product Choice Are Key to Results

September 18th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Understanding the Role of Amino Acids and Proteins in Skin Care

September 14th 2023

First Patient Dosed in Phase 2 Trial of Bempikibart for Alopecia Areata

September 14th 2023

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Periorbital Rejuvenation: Comprehensive Assessment and Product Choice Are Key to Results

September 18th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Understanding the Role of Amino Acids and Proteins in Skin Care

September 14th 2023

First Patient Dosed in Phase 2 Trial of Bempikibart for Alopecia Areata

September 14th 2023

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Periorbital Rejuvenation: Comprehensive Assessment and Product Choice Are Key to Results

September 18th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Understanding the Role of Amino Acids and Proteins in Skin Care

September 14th 2023

First Patient Dosed in Phase 2 Trial of Bempikibart for Alopecia Areata

September 14th 2023
© 2023 MJH Life Sciences

All rights reserved.